

מראה מקום- 304 אנדוקרינולוגיה מבוגרים

מס שאלה	מראה מקום
1	Reference: ADA Standards of care Diabetes Care 2025;48(Supplement 1):S239–S251 Chapter 11. S181-S206 Chapter 9.
2	European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors European Journal of Endocrinology, Volume 189, Issue 1, July 2023. Rec 2.3 ב
3	ature reviews endocrinology Consensus statement https://doi.org/10.1038/s41574-023-00886-5 Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus
4	1.William's 2024, 15th edition, chapter-38, page-1559-1561, figure 38.63. 2. Bae JH. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes Metab J 2025; 49:386-402 https://doi.org/10.4093/dmj.2025.0220
5	ויליאמס 1274-1275
6	ATA Guidelines 2017, DOI: 10.1089/thy.2016.0457
7	Williams Textbook of Endocrinology, 15th ed., Chapter 41: Disorders of Lipoprotein Metabolism, pp. 1656 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes – 2025 Diabetes care 2025; 48(suppl)S3207-S238 Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22
8	Williams 15th edition, chapter 23, p 1118
9	Williams 15th ed, chapter 3, p 382
10	ויליאמס עמוד 1461-1462 פסקה על MIDD ועל WOLFRAM.
11	ויליאמס עמוד 493-טבלה 13.4. עמוד 494-495. עמוד 1717.
12	Consensus on criteria for acromegaly diagnosis and remission. Pituitary (2024) 27:7–22. Table 2 - Key recommendations..
13	Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. Agarwal et al, for the CONFIDENCE Investigators. NEJM June 5, 2025. DOI: 10.1056/NEJMoa2410659 and American Diabetes Association Professional Practice Committee; 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care 1 January 2025; 48 (Supplement 1): S239–S251. https://doi.org/10.2337/dc25-S011
14	International Society for Clinical Densitometry. (2023). 2023 ISCD Official Positions
15	ATA guidelines for the diagnosis and management of thyroid disease during pregnancy and the postpartum. 2017. Page 6 paragraph 3, page 38, recommendation 30
16	Semaglutide 2.4 mg weekly has demonstrated significant weight loss and cardiovascular benefit in patients without diabetes but" "with cardiovascular risk, as in the SELECT trial (Williams Textbook of Endocrinology, 15th ed., Chapter 33, page 1338)
17	1. William's 2024, 15th edition, chapter 15 Target Groups for Hormone Therapy Transdermal Estrogen Transdermal estrogen preparations appear to be as effective as oral estrogens for treating hot flashes and maintaining BMD, but they have different metabolic profiles. Oral estrogens seem to have favorable effects on lipoprotein profiles. However, oral estrogens are associated with several disadvantages, including unfavorable changes in serum levels of triglycerides, C-reactive protein, fibrinogen, factor VII, and plasminogen activator inhibitor type 1.413 Studies suggest a higher risk of venous thromboembolic events among oral HT users compared with transdermal estrogen users who have a minimal risk.413,426 However, clinical trial data that address the effect of transdermal estrogen on CHD and stroke risk are limited.413" 2. Chapter 23 Pubertal induction in females Transdermal estrogen is associated with a better safety profile and reduced cardiovascular events in adult women680 because it avoids the first-pass hepatic effect and subsequent production of clotting factors.
18	1.Tessler FN et al..ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol 2017;14: 587-595 2.Tessler FN et al. Thyroid imaging Reporting and data system (TI-Rads): A User's Guide. Radiology 2018: Volume 287; 1: p29-36 3. William's 2024, 15th edition, chapter-12, page 437-440
19	Williams 15 edition, chapter 41, Disorders of Lipoprotein Metabolism p. 1654, 1657
20	Reference: Williams Textbook, Chapter 7, pp 269
21	Williams 15th edition, fig 13.41
22	1.Williams Textbook 15, Chapter 35, pp 1414-1416. 2.Hyperglycemic Crises in Adults With Diabetes: A Consensus Report Diabetes Care 2024;47:1257–1275 https://doi.org/10.2337/dci24-0032
23	פרק 27 בוליאמס, עמוד 1218
24	William's 2024, 15th edition, chapter-10, page 379; Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479. PMID: 34297684.
25	ויליאמס פרק 39 עמ' 1595-1597
26	ויליאמס עמוד 746 SEX DEVELOPMENT-
27	ויליאמס איור 10.18, עמוד 387.
28	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2021;44(11):2589–2625
29	ספר עמוד 1206
30	Husebye ES et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J endocrinology; 2022 Oct 25;187(6):G1-G21. doi: 10.1530/EJE-22-0689. P G8.
31	Williams 15th edition, pages 1717, box 33.2
32	Williams 15th ed. Ch. 13. p. 484-486
33	Reference: Williams Textbook, Chapter 10, pp 391-392
34	ספר, עמוד 1611 פרק 40.
35	Williams 15th edition chapter 7 p 1208
36	Williams 15th edition chapter 48 p 1794
37	Reference: Expert opinion
38	ויליאמס, עמוד 614, box 15.6
39	Williams 15th edition chapter 12 p 452+454
40	ויליאמס עמוד 609, 1455-איור 37.2. לגבי HOMA-IR יש אזכור בעמוד 1338.

41	Reference: Williams Textbook, Chapter 13, pp 511
42	Cushing Syndrome. A Review. Martin Reincke, MD; JAMA. 2023;330(2):170-181
43	Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
44	Williams Textbook, Chapter 31, pp 1310
45	Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. Brandi, Maria Luisa Arnold, Andrew et al. The Lancet Diabetes & Endocrinology, 2025. Table 3.
46	rec 12-3, ada 2025
47	וויליאמס, פרק 12, עמוד 581, פסקה עליונה מימין
48	Williams 15th edition, chapter 17, pages 686-688, 698, 706-710, 717
49	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2021;44(11):2589–2625
50	2017 ES guidelines on functional hypothalamic amenorrhea, recommendations 3.4+3.7
51	Williams 15th edition, chapter 14, page 548
52	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2021;44(11):2589–2625
53	William's 2024, 15th edition, chapter-8, page 304-309
54	William's 2024, 15th edition, chapter-11, page 424
55	Reference: ADA Standards of care Diabetes Care 2025; 48(Suppl. 1): :S181–S206
56	וויליאמס פרק 43, עמודים 1730-1731, 1722
57	Hembree,et al (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism, 102(11), 3869–3903. https://doi.org/10.1210/je.2017-01658 – Williams, 15th Ed., Chapter 24
58	Reference: ADA Standards of care Diabetes Care 2025;48(Supplement 1):S239–S251 Chapter 11
59	Williams 15th ed, chapter 12, p 463 Tab 12.6
60	Williams 15th edition, chapter 8, pages 395
61	William's 2024, 15th edition, 1338-1340
62	William's 2024, 15th edition, chapter-14, page 555-557
63	Reference: Williams textbook 15 edition Chapter 27, p. 1216
64	ada 2025 chapter 13, 270-274
65	William's 15th edition, pages 141, table 5.2, 159, 185, 435, box 13.1, 1186
66	טבלה 6 ותמונה 2 (עמוד 14), ATA guidelines 2015,
67	וויליאמס עמוד 1539-41 סיבובי סוכרת.
68	1.Williams 15 ed., chapter 17 page 880 paragraph 9 and page 881 paragraph 1 2. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-4088. Page 4060 paragraph 2 and page 4062 paragraph 6
69	וויליאמס פרק 43, עמוד 1733.
70	Diabetes 2020;69:2086–2093 https://doi.org/10.2337/dbi20-0001 Subtypes of Type 2 Diabetes Determined From Clinical Parameters
71	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018 Oct 1;179(4):G1-G46. Recommendation R.5.2. Page G20.
72	Williams 15th ed, chapter 13, p 515
73	ADA 2025 chapter 13, 270-274
74	Williams 15th ed, chapter 27, p 1199
75	Williams 15th ed, chapter 12, p 442
76	Reference: ADA Standards of care Diabetes Care 2025;48(Supplement 1):S266–S282 Chapter 13
77	וויליאמס, עמ' 983 מתייחס לחסר ה-הידרוקסילאז/ עמ' 1097 מתייחס למאייזרורקטינסק/ עמ' 1096 מתייחס ל-CAIS.
78	וויליאמס פרק 43, עמוד 1733, תחת הכותרת "טיפול באינסולינמה"
79	Williams Textbook 15, Chapter 40, pp 1623-1624;ADA Standards of care Diabetes Care 2025;48(Supplement 1):S167–S180 Chapter 8
80	Pituitary incidentaloma: a Pituitary Society international consensus guideline statement, Nature Reviews Endocrinology (2025) , R7-R10, Fig. 1
81	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. Table 2: Summary of medical therapies for Cushing's disease. Page 862. סוף פסקה שנייה משמאל.
82	פרנס: Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocr Rev. 2020 Oct 1;41(5):733–55. doi: 10.1210/edrev/bnaa015. PMID: 32396624; PMCID: PMC7366348.
83	Table 19 from Camacho PM, Petak SM, Binkley N, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY. Endocr Pract. 2020;26(5):564-570. doi:10.4158/GL-2020-0524
84	451 Williams 15th ed, chapter 12 p ATA guidelines 2015 , recommendation 51, p 55
85	Reference: ADA Standards of care Diabetes Care 2025; 48(Suppl. 1):S181–S206 Chapter 9
86	Reference: Williams textbook 15 edition Chapter 13, p. 518-524
87	William's 2024, 15th edition, chapter-4, page 84, chapter 9, page-349, figure 9.14, page 350
88	Ref Williams 15th edition, chapter 10, page 393
89	וויליאמס, עמודים 1298, 1198, 1300
90	עמודים 177 בפרק 6
91	וויליאמס 1462
92	ESE and ES joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency , R2.7+R2.8, G37-G39
93	Reference: Williams Textbook, Chapter 30, pp 1294-1295.
94	Summary of Revisions: Standards of Care in Diabetes 2025, Diabetes Care 2025;48(Supplement 1):S6–S13, Section 10. Cardiovascular Disease and Risk Management, S 11
95	ספר 390,388
96	וויליאמס עמוד 855,893 SEX DEVELOPMENT
97	Ref Williams 15th edition, chapter 4, figure 4.22
98	ATA DTC Guidelines 2015 p 17
99	Camacho PM, Petak SM, Binkley N, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF .POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY. Endocr Pract. 2020;26(5):564-570 doi:10.4158/GL-2020-0524
100	לגבי הקרינה- וויליאמס עמוד 283 לגבי הטיפולים התרופתיים ' טבלה מספר 2 מתוך: A Pituitary Society update to acromegaly management guidelines 2021